BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Discoidin domain receptor tyrosine kinase 1 (DDR1)

January 21, 2016 8:00 AM UTC

Cell culture and mouse studies suggest inhibiting DDR1 could help treat cancers resistant to RG7787. In an RG7787-resistant human skin cancer cell line, RG7787 combined with a DDR1 inhibitor increased cell death compared with RG7787 alone. In mouse xenograft models of RG7787-resistant skin and pancreatic cancers, the combination decreased tumor growth compared with either treatment alone or vehicle. Next steps could include testing DDR1 inhibition in models of other RG7787-resistant cancers...